Nordic Nanovector ASA

Nordic Nanovector ASA

  • Price (EUR)0.073
  • Today's Change0.007 / 9.94%
  • Shares traded0.00
  • 1 Year change-95.23%
  • Beta--
Data delayed at least 15 minutes, as of Mar 22 2023 07:03 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Nordic Nanovector ASA is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

  • Revenue in NOK (TTM)--
  • Net income in NOK--
  • Incorporated2009
  • Employees40.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
Apim Therapeutics AsAnnounced21 Nov 202221 Nov 2022Announced-19.64%--
Apim Therapeutics AsAnnounced09 Nov 202209 Nov 2022Announced-34.78%50.09m
Data delayed at least 15 minutes, as of Mar 21 2023.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.